At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 336 enrolled
Drug / intervention
NOV03 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)
In Brief
A Phase 2 clinical trial evaluating NOV03 and Placebo for Dry Eye Disease (DED). Completed, enrolled 336 participants across 11 sites.
Detailed Summary
This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease (DED)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartJan 2018
Primary CompletionMay 2018
Study CompletionJul 2018
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartJan 3, 2018
Primary CompletionMay 18, 2018
Study CompletionJul 27, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.7 years ago
Interventions
NOV03drug
Perfluorohexyloctane
Placebodrug
Saline solution (0.9% sodium chloride solution)